Women’s Health Bulletin

Published by: Kowsar

Prevalence of Breast Cancer in Isfahan Province, Iran

Zahra Tolou-Ghamari 1 , *
Author Information
1 Isfahan Kidney Transplantation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Article information
  • Women’s Health Bulletin: October 2018, 5 (4); e82678
  • Published Online: September 3, 2018
  • Article Type: Research Article
  • Received: July 29, 2018
  • Revised: August 21, 2018
  • Accepted: August 28, 2018
  • DOI: 10.5812/whb.82678

To Cite: Tolou-Ghamari Z. Prevalence of Breast Cancer in Isfahan Province, Iran, Women Health Bull. 2018 ; 5(4):e82678. doi: 10.5812/whb.82678.

Abstract
Copyright © 2018, Women’s Health Bulletin. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Bhikoo R, Srinivasa S, Yu TC, Moss D, Hill AG. Systematic review of breast cancer biology in developing countries (part 1): Africa, the Middle East, Eastern Europe, Mexico, the Caribbean and South America. Cancers (Basel). 2011;3(2):2358-381. doi: 10.3390/cancers3022358. [PubMed: 24212814]. [PubMed Central: PMC3757422].
  • 2. The Lancet. Breast cancer in developing countries. Lancet. 2009;374(9701):1567. doi: 10.1016/s0140-6736(09)61930-9.
  • 3. Berek J. Female genital disease. Williams & Wilkins, Lippincott; 2012.
  • 4. Ferlay JSH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer incidence and mortality worldwide. Lyon, France: IARC Scientific Publications (International Agency for Research on Cancer); 2008. Report No.: IARC Cancer Base No 10. Available from: http://globocan.iarc.fr/.
  • 5. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13(4):383-91. doi: 10.1111/j.1524-4741.2007.00446.x. [PubMed: 17593043].
  • 6. Al-Eid H, Arteh S. Cancer incidence report Saudi Arabia. Riyadh, Kingdom of Saudi Arabia: Ministry of Health, Saudi Cancer Registry; 2005. 98 p.
  • 7. Enayatrad M, Amoori N, Salehiniya H. Epidemiology and trends in breast cancer mortality in iran. Iran J Public Health. 2015;44(3):430-1. [PubMed: 25905094]. [PubMed Central: PMC4402429].
  • 8. Jazayeri SB, Saadat S, Ramezani R, Kaviani A. Incidence of primary breast cancer in Iran: Ten-year national cancer registry data report. Cancer Epidemiol. 2015;39(4):519-27. doi: 10.1016/j.canep.2015.04.016. [PubMed: 26070507].
  • 9. Newman LA. Breast cancer disparities: Socioeconomic factors versus biology. Ann Surg Oncol. 2017;24(10):2869-75. doi: 10.1245/s10434-017-5977-1. [PubMed: 28766222].
  • 10. Mazdak H, Tolou-Ghamari Z. Preliminary study of prevalence for bladder cancer in Isfahan Province, Iran. Arab J Urol. 2018;16(2):206-10. doi: 10.1016/j.aju.2017.11.017. [PubMed: 29892483]. [PubMed Central: PMC5992262].
  • 11. Tolou Ghamari Z. Prevalence of lung cancer in Isfahan Province, Iran. J Egypt Natl Canc Inst. 2018;30(2):57-9. doi: 10.1016/j.jnci.2018.03.001. [PubMed: 29691096].
  • 12. Tolou-Ghamari Z, Palizban AA, Michael Tredger J. Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoassay. Drugs R D. 2004;5(1):17-22. [PubMed: 14725486].
  • 13. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237-49. doi: 10.1053/j.seminoncol.2009.03.001. [PubMed: 19460581]. [PubMed Central: PMC2894028].
  • 14. Destounis S, Santacroce A. Age to begin and intervals for breast cancer screening: Balancing benefits and harms. AJR Am J Roentgenol. 2018;210(2):279-84. doi: 10.2214/AJR.17.18730. [PubMed: 29064754].
  • 15. Ebrahimi M, Vahdaninia M, Montazeri A. Risk factors for breast cancer in Iran: a case-control study. Breast Cancer Res. 2002;4(5):R10. [PubMed: 12223127]. [PubMed Central: PMC125302].
  • 16. Balekouzou A, Yin P, Pamatika CM, Bishwajit G, Nambei SW, Djeintote M, et al. Epidemiology of breast cancer: retrospective study in the Central African Republic. BMC Public Health. 2016;16(1):1230. doi: 10.1186/s12889-016-3863-6. [PubMed: 27923361]. [PubMed Central: PMC5142143].
  • 17. Shao S, Gill AA, Zahm SH, Jatoi I, Shriver CD, McGlynn KA, et al. Diabetes and overall survival among breast cancer patients in the U.S. Military Health System. Canc Epidemiol Biomarkers Prev. 2018;27(1):50-7. doi: 10.1158/1055-9965.epi-17-0439.
  • 18. Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1-32. doi: 10.1016/bs.pmbts.2017.07.002. [PubMed: 29096890].
  • 19. Seiffert K, Schmalfeldt B, Muller V. [Current status of targeted treatment in breast cancer]. Dtsch Med Wochenschr. 2017;142(22):1669-75. German. doi: 10.1055/s-0043-108468. [PubMed: 29078212].
  • 20. Lucchesi S, Marciano I, Panagia P, Intelisano R, Randazzo MP, Sgroi C, et al. Author correction to: Prevalence of use and cost of biological drugs for cancer treatment: A 5-year picture from southern Italy. Clin Drug Investig. 2018;38(3):279-85. doi: 10.1007/s40261-017-0613-1. [PubMed: 29289999]. [PubMed Central: PMC5834583].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments